The function works with procotol- and results- related information.
It converts lists and other values that are in a data frame returned
by dbGetFieldsIntoDf into individual rows of a long data frame.
From the resulting data frame, values of interest can be selected
using dfName2Value.
The function is intended for fields with complex content, such as node
field "clinical_results
" from EUCTR, which dbGetFieldsIntoDf
returns as a multiply nested list and for which this function then
converts every observation of every (leaf) field into a row of its own.
Arguments
- df
Data frame (or tibble) with columns including the trial identifier (
_id
) and one or more variables as obtained from dbGetFieldsIntoDf
Value
A data frame (or tibble, if dplyr
is loaded)
with the four columns: `_id`, `identifier`, `name`, `value`
Examples
dbc <- nodbi::src_sqlite(
dbname = system.file("extdata", "demo.sqlite", package = "ctrdata"),
collection = "my_trials")
dfwide <- dbGetFieldsIntoDf(
fields = "clinical_results.participant_flow",
con = dbc)
#> clinical_results.participant_flow...
#>
#> .
dfTrials2Long(df = dfwide)
#> clinical_results.participant_flow
#>
#> .
#> .
#> .
#> .
#> .
#>
#> Total 342 rows, 13 unique names of variables
#> _id identifier
#> 1 NCT01389856 0
#> 2 NCT01389856 0
#> 3 NCT01389856 1
#> 4 NCT01389856 2
#> 5 NCT01389856 1
#> 6 NCT01389856 2
#> 7 NCT01389856 1
#> 8 NCT01389856 2
#> 9 NCT01389856 0
#> 10 NCT01389856 1
#> 11 NCT01389856 2
#> 12 NCT01389856 3
#> 13 NCT01389856 11
#> 14 NCT01389856 12
#> 15 NCT01389856 2.1
#> 16 NCT01389856 2.2
#> 17 NCT01389856 2.1
#> 18 NCT01389856 2.2
#> 19 NCT01389856 3.1
#> 20 NCT01389856 3.2
#> 21 NCT01389856 3.1
#> 22 NCT01389856 3.2
#> 23 NCT01490580 0
#> 24 NCT01490580 1
#> 25 NCT01490580 2
#> 26 NCT01490580 1
#> 27 NCT01490580 2
#> 28 NCT01490580 1
#> 29 NCT01490580 2
#> 30 NCT01490580 0
#> 31 NCT01490580 1
#> 32 NCT01490580 2
#> 33 NCT01490580 3
#> 34 NCT01490580 1.1
#> 35 NCT01490580 1.2
#> 36 NCT01490580 1.1
#> 37 NCT01490580 1.2
#> 38 NCT01490580 2.1
#> 39 NCT01490580 2.2
#> 40 NCT01490580 2.1
#> 41 NCT01490580 2.2
#> 42 NCT01490580 3.1
#> 43 NCT01490580 3.2
#> 44 NCT01490580 3.1
#> 45 NCT01490580 3.2
#> 46 NCT01490580 0
#> 47 NCT01490580 1
#> 48 NCT01490580 2
#> 49 NCT01490580 1
#> 50 NCT01490580 2
#> 51 NCT01555957 1
#> 52 NCT01555957 2
#> 53 NCT01555957 1
#> 54 NCT01555957 2
#> 55 NCT01555957 1
#> 56 NCT01555957 2
#> 57 NCT01555957 0
#> 58 NCT01555957 1
#> 59 NCT01555957 2
#> 60 NCT01555957 3
#> 61 NCT01555957 1.1
#> 62 NCT01555957 1.2
#> 63 NCT01555957 1.1
#> 64 NCT01555957 1.2
#> 65 NCT01555957 2.1
#> 66 NCT01555957 2.2
#> 67 NCT01555957 2.1
#> 68 NCT01555957 2.2
#> 69 NCT01555957 3.1
#> 70 NCT01555957 3.2
#> 71 NCT01555957 3.1
#> 72 NCT01555957 3.2
#> 73 NCT01720524 0
#> 74 NCT01720524 0
#> 75 NCT01720524 1
#> 76 NCT01720524 2
#> 77 NCT01720524 1
#> 78 NCT01720524 2
#> 79 NCT01720524 1
#> 80 NCT01720524 2
#> 81 NCT01720524 1
#> 82 NCT01720524 2
#> 83 NCT01720524 1.1
#> 84 NCT01720524 1.2
#> 85 NCT01720524 1.3
#> 86 NCT01720524 1.1.1
#> 87 NCT01720524 1.1.2
#> 88 NCT01720524 1.1.1
#> 89 NCT01720524 1.1.2
#> 90 NCT01720524 1.2.1
#> 91 NCT01720524 1.2.2
#> 92 NCT01720524 1.2.1
#> 93 NCT01720524 1.2.2
#> 94 NCT01720524 1.3.1
#> 95 NCT01720524 1.3.2
#> 96 NCT01720524 1.3.1
#> 97 NCT01720524 1.3.2
#> 98 NCT01720524 2.1
#> 99 NCT01720524 2.2
#> 100 NCT01720524 2.3
#> 101 NCT01720524 2.11
#> 102 NCT01720524 2.12
#> 103 NCT01720524 2.2.1
#> 104 NCT01720524 2.2.2
#> 105 NCT01720524 2.2.1
#> 106 NCT01720524 2.2.2
#> 107 NCT01720524 2.3.1
#> 108 NCT01720524 2.3.2
#> 109 NCT01720524 2.3.1
#> 110 NCT01720524 2.3.2
#> 111 NCT01720524 1.1
#> 112 NCT01720524 1.2
#> 113 NCT01720524 1.3
#> 114 NCT01720524 1.4
#> 115 NCT01720524 1.5
#> 116 NCT01720524 1.6
#> 117 NCT01720524 1.7
#> 118 NCT01720524 1.8
#> 119 NCT01720524 1.1.1
#> 120 NCT01720524 1.1.2
#> 121 NCT01720524 1.1.1
#> 122 NCT01720524 1.1.2
#> 123 NCT01720524 1.2.1
#> 124 NCT01720524 1.2.2
#> 125 NCT01720524 1.2.1
#> 126 NCT01720524 1.2.2
#> 127 NCT01720524 1.3.1
#> 128 NCT01720524 1.3.2
#> 129 NCT01720524 1.3.1
#> 130 NCT01720524 1.3.2
#> 131 NCT01720524 1.4.1
#> 132 NCT01720524 1.4.2
#> 133 NCT01720524 1.4.1
#> 134 NCT01720524 1.4.2
#> 135 NCT01720524 1.5.1
#> 136 NCT01720524 1.5.2
#> 137 NCT01720524 1.5.1
#> 138 NCT01720524 1.5.2
#> 139 NCT01720524 1.6.1
#> 140 NCT01720524 1.6.2
#> 141 NCT01720524 1.6.1
#> 142 NCT01720524 1.6.2
#> 143 NCT01720524 1.7.1
#> 144 NCT01720524 1.7.2
#> 145 NCT01720524 1.7.1
#> 146 NCT01720524 1.7.2
#> 147 NCT01720524 1.8.1
#> 148 NCT01720524 1.8.2
#> 149 NCT01720524 1.8.1
#> 150 NCT01720524 1.8.2
#> 151 NCT01720524 2.1
#> 152 NCT01720524 2.2
#> 153 NCT01720524 2.3
#> 154 NCT01720524 2.4
#> 155 NCT01720524 2.1.1
#> 156 NCT01720524 2.1.2
#> 157 NCT01720524 2.1.1
#> 158 NCT01720524 2.1.2
#> 159 NCT01720524 2.2.1
#> 160 NCT01720524 2.2.2
#> 161 NCT01720524 2.2.1
#> 162 NCT01720524 2.2.2
#> 163 NCT01720524 2.3.1
#> 164 NCT01720524 2.3.2
#> 165 NCT01720524 2.3.1
#> 166 NCT01720524 2.3.2
#> 167 NCT01720524 2.4.1
#> 168 NCT01720524 2.4.2
#> 169 NCT01720524 2.4.1
#> 170 NCT01720524 2.4.2
#> 171 NCT01783041 0
#> 172 NCT01783041 1
#> 173 NCT01783041 2
#> 174 NCT01783041 1
#> 175 NCT01783041 2
#> 176 NCT01783041 1
#> 177 NCT01783041 2
#> 178 NCT01783041 1
#> 179 NCT01783041 2
#> 180 NCT01783041 1.1
#> 181 NCT01783041 1.2
#> 182 NCT01783041 1.3
#> 183 NCT01783041 1.1.1
#> 184 NCT01783041 1.1.2
#> 185 NCT01783041 1.1.1
#> 186 NCT01783041 1.1.2
#> 187 NCT01783041 1.2.1
#> 188 NCT01783041 1.2.2
#> 189 NCT01783041 1.2.1
#> 190 NCT01783041 1.2.2
#> 191 NCT01783041 1.3.1
#> 192 NCT01783041 1.3.2
#> 193 NCT01783041 1.3.1
#> 194 NCT01783041 1.3.2
#> 195 NCT01783041 2.1
#> 196 NCT01783041 2.2
#> 197 NCT01783041 2.3
#> 198 NCT01783041 2.1.1
#> 199 NCT01783041 2.1.2
#> 200 NCT01783041 2.1.1
#> 201 NCT01783041 2.1.2
#> 202 NCT01783041 2.2.1
#> 203 NCT01783041 2.2.2
#> 204 NCT01783041 2.2.1
#> 205 NCT01783041 2.2.2
#> 206 NCT01783041 2.3.1
#> 207 NCT01783041 2.3.2
#> 208 NCT01783041 2.3.1
#> 209 NCT01783041 2.3.2
#> 210 NCT01899677 1
#> 211 NCT01899677 2
#> 212 NCT01899677 1
#> 213 NCT01899677 2
#> 214 NCT01899677 1
#> 215 NCT01899677 2
#> 216 NCT01899677 0
#> 217 NCT01899677 1
#> 218 NCT01899677 2
#> 219 NCT01899677 3
#> 220 NCT01899677 1.1
#> 221 NCT01899677 1.2
#> 222 NCT01899677 1.1
#> 223 NCT01899677 1.2
#> 224 NCT01899677 2.1
#> 225 NCT01899677 2.2
#> 226 NCT01899677 2.1
#> 227 NCT01899677 2.2
#> 228 NCT01899677 3.1
#> 229 NCT01899677 3.2
#> 230 NCT01899677 3.1
#> 231 NCT01899677 3.2
#> 232 NCT01954082 0
#> 233 NCT01954082 1
#> 234 NCT01954082 2
#> 235 NCT01954082 1
#> 236 NCT01954082 2
#> 237 NCT01954082 1
#> 238 NCT01954082 2
#> 239 NCT01954082 0
#> 240 NCT01954082 1
#> 241 NCT01954082 2
#> 242 NCT01954082 3
#> 243 NCT01954082 4
#> 244 NCT01954082 1.1
#> 245 NCT01954082 1.2
#> 246 NCT01954082 1.1
#> 247 NCT01954082 1.2
#> 248 NCT01954082 21
#> 249 NCT01954082 22
#> 250 NCT01954082 31
#> name
#> 1 clinical_results.participant_flow.recruitment_details
#> 2 clinical_results.participant_flow.pre_assignment_details
#> 3 clinical_results.participant_flow.group_list.group.group_id
#> 4 clinical_results.participant_flow.group_list.group.group_id
#> 5 clinical_results.participant_flow.group_list.group.title
#> 6 clinical_results.participant_flow.group_list.group.title
#> 7 clinical_results.participant_flow.group_list.group.description
#> 8 clinical_results.participant_flow.group_list.group.description
#> 9 clinical_results.participant_flow.period_list.period.title
#> 10 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 11 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 12 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 13 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants
#> 14 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants
#> 15 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 16 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 17 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 18 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 19 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 20 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 21 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 22 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 23 clinical_results.participant_flow.recruitment_details
#> 24 clinical_results.participant_flow.group_list.group.group_id
#> 25 clinical_results.participant_flow.group_list.group.group_id
#> 26 clinical_results.participant_flow.group_list.group.title
#> 27 clinical_results.participant_flow.group_list.group.title
#> 28 clinical_results.participant_flow.group_list.group.description
#> 29 clinical_results.participant_flow.group_list.group.description
#> 30 clinical_results.participant_flow.period_list.period.title
#> 31 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 32 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 33 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 34 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 35 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 36 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 37 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 38 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 39 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 40 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 41 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 42 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 43 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 44 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 45 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 46 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 47 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 48 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 49 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 50 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 51 clinical_results.participant_flow.group_list.group.group_id
#> 52 clinical_results.participant_flow.group_list.group.group_id
#> 53 clinical_results.participant_flow.group_list.group.title
#> 54 clinical_results.participant_flow.group_list.group.title
#> 55 clinical_results.participant_flow.group_list.group.description
#> 56 clinical_results.participant_flow.group_list.group.description
#> 57 clinical_results.participant_flow.period_list.period.title
#> 58 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 59 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 60 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 61 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 62 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 63 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 64 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 65 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 66 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 67 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 68 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 69 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 70 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 71 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 72 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 73 clinical_results.participant_flow.recruitment_details
#> 74 clinical_results.participant_flow.pre_assignment_details
#> 75 clinical_results.participant_flow.group_list.group.group_id
#> 76 clinical_results.participant_flow.group_list.group.group_id
#> 77 clinical_results.participant_flow.group_list.group.title
#> 78 clinical_results.participant_flow.group_list.group.title
#> 79 clinical_results.participant_flow.group_list.group.description
#> 80 clinical_results.participant_flow.group_list.group.description
#> 81 clinical_results.participant_flow.period_list.period.title
#> 82 clinical_results.participant_flow.period_list.period.title
#> 83 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 84 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 85 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 86 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 87 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 88 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 89 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 90 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 91 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 92 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 93 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 94 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 95 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 96 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 97 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 98 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 99 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 100 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 101 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants
#> 102 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants
#> 103 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 104 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 105 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 106 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 107 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 108 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 109 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 110 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 111 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 112 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 113 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 114 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 115 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 116 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 117 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 118 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 119 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 120 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 121 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 122 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 123 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 124 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 125 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 126 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 127 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 128 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 129 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 130 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 131 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 132 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 133 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 134 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 135 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 136 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 137 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 138 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 139 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 140 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 141 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 142 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 143 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 144 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 145 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 146 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 147 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 148 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 149 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 150 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 151 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 152 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 153 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 154 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.title
#> 155 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 156 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 157 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 158 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 159 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 160 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 161 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 162 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 163 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 164 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 165 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 166 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 167 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 168 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.group_id
#> 169 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 170 clinical_results.participant_flow.period_list.period.drop_withdraw_reason_list.drop_withdraw_reason.participants_list.participants.count
#> 171 clinical_results.participant_flow.recruitment_details
#> 172 clinical_results.participant_flow.group_list.group.group_id
#> 173 clinical_results.participant_flow.group_list.group.group_id
#> 174 clinical_results.participant_flow.group_list.group.title
#> 175 clinical_results.participant_flow.group_list.group.title
#> 176 clinical_results.participant_flow.group_list.group.description
#> 177 clinical_results.participant_flow.group_list.group.description
#> 178 clinical_results.participant_flow.period_list.period.title
#> 179 clinical_results.participant_flow.period_list.period.title
#> 180 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 181 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 182 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 183 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 184 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 185 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 186 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 187 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 188 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 189 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 190 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 191 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 192 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 193 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 194 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 195 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 196 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 197 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 198 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 199 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 200 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 201 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 202 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 203 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 204 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 205 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 206 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 207 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 208 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 209 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 210 clinical_results.participant_flow.group_list.group.group_id
#> 211 clinical_results.participant_flow.group_list.group.group_id
#> 212 clinical_results.participant_flow.group_list.group.title
#> 213 clinical_results.participant_flow.group_list.group.title
#> 214 clinical_results.participant_flow.group_list.group.description
#> 215 clinical_results.participant_flow.group_list.group.description
#> 216 clinical_results.participant_flow.period_list.period.title
#> 217 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 218 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 219 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 220 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 221 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 222 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 223 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 224 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 225 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 226 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 227 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 228 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 229 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 230 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 231 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 232 clinical_results.participant_flow.recruitment_details
#> 233 clinical_results.participant_flow.group_list.group.group_id
#> 234 clinical_results.participant_flow.group_list.group.group_id
#> 235 clinical_results.participant_flow.group_list.group.title
#> 236 clinical_results.participant_flow.group_list.group.title
#> 237 clinical_results.participant_flow.group_list.group.description
#> 238 clinical_results.participant_flow.group_list.group.description
#> 239 clinical_results.participant_flow.period_list.period.title
#> 240 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 241 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 242 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 243 clinical_results.participant_flow.period_list.period.milestone_list.milestone.title
#> 244 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 245 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.group_id
#> 246 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 247 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants.count
#> 248 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants
#> 249 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants
#> 250 clinical_results.participant_flow.period_list.period.milestone_list.milestone.participants_list.participants
#> value
#> 1 First patient, first visit was 8 December 2011 and last patient, last visit was 5 December 2013. The investigational sites were tertiary care centers with neonatal intensive care unit facilities at which inhaled nitric oxide (iNO) was used as standard of care for persistent pulmonary hypertension of the newborn (PPHN).
#> 2 Term or near-term (gestational age > 34 weeks) hypoxic newborns with respiratory distress refractory to supplemental oxygen were considered, provided they had no significant structural cardiac anomalies documented in the pre-natal period and had no immediate need for extra corporeal membrane oxygenation (ECMO).
#> 3 P1
#> 4 P2
#> 5 Bosentan
#> 6 Placebo
#> 7 Bosentan\rBosentan: 2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
#> 8 Matching placebo\rMatching placebo: twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
#> 9 Overall Study
#> 10 STARTED
#> 11 COMPLETED
#> 12 NOT COMPLETED
#> 13 Randomized and treated. An additional 2 patients were randomized but not treated.
#> 14 Randomized and treated.
#> 15 P1
#> 16 P2
#> 17 13
#> 18 8
#> 19 P1
#> 20 P2
#> 21 0
#> 22 0
#> 23 The trial was prematurely interrupted for logistic reasons in July 2016: a fourth drug manufacturing run was necessary because the intralipids had passed their expiration date and funding had run out. During the study period, 755 patients were screened for eligibility, and 173 randomized
#> 24 P1
#> 25 P2
#> 26 Atropine Atracurium Sufentanil
#> 27 Atropine Propofol
#> 28 n=82 allocated to atropine+atracurium+sufentanil\rn=80 received allocated intervention\rn=2 did not receive allocated intervention\rn=1 never intubated\rn=1 received another premedication\r82 included in final analysis
#> 29 n=91 allocated to atropine+propofol\rn= 2 excluded for lack of consent\rn=83 received allocated intervention\rn=6 did not receive allocated intervention\rn=2 never intubated\rn=4 received another premedication\r89 included in final analysis
#> 30 Overall Study
#> 31 STARTED
#> 32 COMPLETED
#> 33 NOT COMPLETED
#> 34 P1
#> 35 P2
#> 36 82
#> 37 91
#> 38 P1
#> 39 P2
#> 40 82
#> 41 89
#> 42 P1
#> 43 P2
#> 44 0
#> 45 2
#> 46 Parents withdrew consent
#> 47 P1
#> 48 P2
#> 49 0
#> 50 2
#> 51 P1
#> 52 P2
#> 53 Low Dose Intravenous Lipids
#> 54 High Dose of Intravenous Lipids
#> 55 intravenous lipid: intravenous given daily for 6 weeks
#> 56 intravenous lipid: intravenous given daily for 6 weeks
#> 57 Overall Study
#> 58 STARTED
#> 59 COMPLETED
#> 60 NOT COMPLETED
#> 61 P1
#> 62 P2
#> 63 20
#> 64 20
#> 65 P1
#> 66 P2
#> 67 20
#> 68 20
#> 69 P1
#> 70 P2
#> 71 0
#> 72 0
#> 73 This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).
#> 74 Neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure (HRF) and at risk of PPHN who were receiving inhaled nitric oxide (iNO) treatment were evaluated in this study.
#> 75 P1
#> 76 P2
#> 77 IV Sildenafil
#> 78 Placebo
#> 79 Part A: Participants received sildenafil intravenously based on their body weight at a loading dose of 0.1 milligrams per kg (mg/kg) for 30 minutes on Day 1 followed by a maintenance dose of 0.03 milligrams per kg per hour (mg/kg/hr), for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.
#> 80 Participants received placebo (0.9 % normal saline or dextrose 10%) at a rate matched to sildenafil infusion, intravenously, based on participant's weight, for a minimum of 2 days and maximum of 14 days. Infusion continuation was upon investigator discretion in view of participants' safety and well-being. Part B: Participants who started Part A (not necessarily completed Part A) and who were eligible and consented, continued to be followed up in part B of the study.
#> 81 Part A
#> 82 Part B
#> 83 STARTED
#> 84 COMPLETED
#> 85 NOT COMPLETED
#> 86 P1
#> 87 P2
#> 88 29
#> 89 30
#> 90 P1
#> 91 P2
#> 92 22
#> 93 18
#> 94 P1
#> 95 P2
#> 96 7
#> 97 12
#> 98 STARTED
#> 99 COMPLETED
#> 100 NOT COMPLETED
#> 101 Participants who did not complete Part A could also participate in Part B.
#> 102 Participants who did not complete Part A could also participate in Part B.
#> 103 P1
#> 104 P2
#> 105 22
#> 106 17
#> 107 P1
#> 108 P2
#> 109 5
#> 110 9
#> 111 Insufficient Clinical Response
#> 112 Adverse Event
#> 113 Death
#> 114 Lost to Follow-up
#> 115 Missed 28 day follow-up visit
#> 116 Withdrawal by Subject
#> 117 Other
#> 118 Lost to Follow-up
#> 119 P1
#> 120 P2
#> 121 2
#> 122 4
#> 123 P1
#> 124 P2
#> 125 2
#> 126 2
#> 127 P1
#> 128 P2
#> 129 2
#> 130 1
#> 131 P1
#> 132 P2
#> 133 0
#> 134 1
#> 135 P1
#> 136 P2
#> 137 1
#> 138 1
#> 139 P1
#> 140 P2
#> 141 0
#> 142 1
#> 143 P1
#> 144 P2
#> 145 0
#> 146 1
#> 147 P1
#> 148 P2
#> 149 0
#> 150 1
#> 151 No longer willing to participate in study
#> 152 Other
#> 153 Lost to Follow-up
#> 154 Death
#> 155 P1
#> 156 P2
#> 157 1
#> 158 4
#> 159 P1
#> 160 P2
#> 161 2
#> 162 0
#> 163 P1
#> 164 P2
#> 165 2
#> 166 3
#> 167 P1
#> 168 P2
#> 169 0
#> 170 2
#> 171 Infants born at <32 weeks gestation admitted to the Neonatal Intensive Care Unit (NICU) at Weiler and Wakefield Divisions of Montefiore Medical Center were enrolled in this study.
#> 172 P1
#> 173 P2
#> 174 5% Dextrose
#> 175 L-carnitine
#> 176 Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.\r5% Dextrose: Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
#> 177 Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.\rL-carnitine: Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
#> 178 First 2 Weeks of Life
#> 179 NNNS Examination at Term Equivalent Age
#> 180 STARTED
#> 181 COMPLETED
#> 182 NOT COMPLETED
#> 183 P1
#> 184 P2
#> 185 72
#> 186 72
#> 187 P1
#> 188 P2
#> 189 69
#> 190 71
#> 191 P1
#> 192 P2
#> 193 3
#> 194 1
#> 195 STARTED
#> 196 COMPLETED
#> 197 NOT COMPLETED
#> 198 P1
#> 199 P2
#> 200 69
#> 201 71
#> 202 P1
#> 203 P2
#> 204 60
#> 205 59
#> 206 P1
#> 207 P2
#> 208 9
#> 209 12
#> 210 P1
#> 211 P2
#> 212 Symbiotic
#> 213 Distilled Water
#> 214 symbiotic preparation 1/2 sachet twice daily during 30 days\rsymbiotic: Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
#> 215 2 x 0.5 cc distilled water will be given during 30 days\rdistilled water: 0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
#> 216 Overall Study
#> 217 STARTED
#> 218 COMPLETED
#> 219 NOT COMPLETED
#> 220 P1
#> 221 P2
#> 222 35
#> 223 35
#> 224 P1
#> 225 P2
#> 226 25
#> 227 28
#> 228 P1
#> 229 P2
#> 230 10
#> 231 7
#> 232 From April 2014 to September 2015, infants born before 28 weeks gestation and surviving >12 hours were screened when admitted to one of the 18 NICHD NRN Centers (approximately 44 sites) in the United States and enrolled in the study if they met the eligibility criteria and consent was obtained before 72 hours postnatal age.
#> 233 P1
#> 234 P2
#> 235 Myo-Inositol 5% Injection
#> 236 5% Glucose(Dextrose)
#> 237 Inositol (i.e myo-Inositol) 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. The medication is administered twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose) begining within 12-72 hours of birth and continuing until the earliest of 34 weeks postmenstrual age (PMA), 10 weeks chronologic age, or the time of discharge. The doses are administered intravenously (IV) using syringe pump over 15-30 minutes until enteral feeds reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at which time the same dose and formulation will be administered enterally.
#> 238 The placebo is 5% dextrose (5% glucose) in sterile water (D5W pyrogen and preservative free) United States Pharmacopoeia (USP) for IV infusion. The placebo is administered in the same dose (80 mg glucose/kg/day divided in 2 doses administered every 12 hours) and dispensed in the same manner (intravenously or enterally) as the inositol.
#> 239 Overall Study
#> 240 STARTED
#> 241 Treated
#> 242 COMPLETED
#> 243 NOT COMPLETED
#> 244 P1
#> 245 P2
#> 246 317
#> 247 321
#> 248 The 4 participants who were not treated either died (3) or withdrew before treatment start (1).
#> 249 The 2 participants who were not treated died before treatment start.
#> 250 There were 22 infants that received more doses than intended per protocol.
#> [ reached 'max' / getOption("max.print") -- omitted 92 rows ]